FLT1 and hepatocellular carcinoma: Sorafenib, a small molecule inhibitor of multiple kinases, including Raf-1, B-Raf, vascular endothelial growth factor receptors 1-3 (VEGFR1-3), platelet-derived growth factor receptor β (PDGFRβ) and Bcr-Abl and of the non-kinase STAT3, is the only FDA approved treatment option for advanced HCC [4–7].